Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Change in Accured Expenses (2016 - 2025)

Aptevo Therapeutics' Change in Accured Expenses history spans 11 years, with the latest figure at $724000.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 56.03% year-over-year to $724000.0; the TTM value through Sep 2025 reached -$267000.0, up 71.95%, while the annual FY2024 figure was -$1.0 million, 296.33% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $724000.0 at Aptevo Therapeutics, up from -$501000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.1 million in Q2 2023 and bottomed at -$2.1 million in Q1 2021.
  • The 5-year median for Change in Accured Expenses is -$76000.0 (2023), against an average of -$178894.7.
  • The largest annual shift saw Change in Accured Expenses tumbled 3345.24% in 2022 before it soared 710.53% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$220000.0 in 2021, then soared by 549.55% to $989000.0 in 2022, then plummeted by 60.67% to $389000.0 in 2023, then dropped by 16.71% to $324000.0 in 2024, then skyrocketed by 123.46% to $724000.0 in 2025.
  • Per Business Quant, the three most recent readings for APVO's Change in Accured Expenses are $724000.0 (Q3 2025), -$501000.0 (Q2 2025), and -$814000.0 (Q1 2025).